Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17135333 | ULTRA-LONG ACTING INSULIN-FC FUSION PROTEINS AND METHODS OF USE | December 2020 | August 2021 | Allow | 8 | 2 | 1 | No | No |
| 17135684 | Stabilized Composition | December 2020 | July 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17254859 | A RECONSTITUTABLE TEVERELIX-TFA COMPOSITION | December 2020 | December 2022 | Allow | 24 | 3 | 1 | Yes | No |
| 17124483 | Weight Loss Regimen | December 2020 | May 2023 | Allow | 29 | 2 | 1 | Yes | Yes |
| 17111707 | METHODS FOR PROTECTING AND TREATING TRAUMATIC BRAIN INJURY, CONCUSSION AND BRAIN INFLAMMATION WITH INTRANASAL INSULIN | December 2020 | March 2021 | Allow | 3 | 1 | 0 | No | No |
| 17109828 | STABLE LIQUID FORMULATIONS OF GLUCAGON-LIKE PEPTIDE 1 OR ANALOGUES THEREOF | December 2020 | May 2021 | Allow | 5 | 1 | 1 | Yes | No |
| 15734044 | METHOD AND USE OF CONTROLLING POSTPRANDIAL GLUCOSE LEVELS IN A SUBJECT | December 2020 | March 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17105399 | METHOD OF TREATING DIABETES TYPE 2 BY ADMINISTERING ULTRARAPID ACTING INSULIN | November 2020 | January 2024 | Allow | 38 | 4 | 1 | No | No |
| 17102329 | A METHOD OF REDUCING BLOOD GLUCOSE LEVELS AND INHIBITING SECRETED aP2 | November 2020 | February 2023 | Allow | 27 | 1 | 1 | No | No |
| 17053511 | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid | November 2020 | October 2022 | Allow | 23 | 1 | 1 | Yes | No |
| 17089993 | Novel Acylated Insulin Analogues and Uses Thereof | November 2020 | December 2022 | Abandon | 25 | 0 | 1 | No | No |
| 17089366 | METHOD OF DELIVERING GONADOTROPIN RELEASING HORMONE OR AN ANALOGUE THEREOF INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE | November 2020 | January 2023 | Allow | 26 | 1 | 0 | No | No |
| 17051241 | GLUCOSE TRANSPORTER 4 ANTIBODIES, METHODS OF MAKING THE SAME, AND USES THEREOF | October 2020 | August 2023 | Allow | 33 | 1 | 1 | Yes | No |
| 15733776 | GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF | October 2020 | May 2023 | Allow | 31 | 2 | 0 | No | Yes |
| 17077813 | PREPARATION COMPRISING EXANATIDE FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT | October 2020 | February 2023 | Allow | 28 | 1 | 0 | No | No |
| 17071791 | ACTIVIN-ACTRIIA ANTAGONISTS AND USES FOR TREATING MULTIPLE MYELOMA | October 2020 | April 2023 | Abandon | 30 | 1 | 0 | No | No |
| 17069521 | METHODS COMPRISING CONTINUOUS ADMINISTRATION OF EXENATIDE AND CO-ADMINISTRATION OF A DRUG | October 2020 | January 2023 | Allow | 27 | 1 | 0 | No | No |
| 17046686 | GCGR ANTIBODY AND GLP-1 FUSION PROTEIN THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | October 2020 | August 2022 | Allow | 22 | 1 | 1 | No | No |
| 17046013 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HYPERGLYCEMIA, INSULIN RESISTANCE, AND ASSOCIATED ORGAN DAMAGE | October 2020 | September 2022 | Abandon | 24 | 1 | 1 | No | No |
| 17045724 | COMPOSITIONS FOR TREATING KIDNEY DISEASE | October 2020 | May 2024 | Abandon | 44 | 2 | 1 | No | Yes |
| 17032706 | COMBINED USE OF GDF TRAPS AND ERYTHROPOIETIN RECEPTOR ACTIVATORS TO INCREASE RED BLOOD CELL LEVELS | September 2020 | June 2022 | Abandon | 21 | 1 | 0 | No | No |
| 16977448 | INSULIN-LOADED METAL-ORGANIC FRAMEWORKS | September 2020 | January 2023 | Allow | 29 | 1 | 1 | Yes | No |
| 16976435 | PRODUCTION AND USE OF EXTRACELLULAR VESICLES | August 2020 | September 2024 | Abandon | 49 | 1 | 1 | No | No |
| 17004395 | ANTIBODY PEPTIDE CONJUGATES THAT HAVE AGONIST ACTIVITY AT BOTH THE GLUCAGON AND GLUCAGON-LIKE PEPTIDE 1 RECEPTORS | August 2020 | May 2023 | Allow | 33 | 2 | 1 | No | No |
| 17002571 | Self Assembling Protein Nanoparticles as Carrier Molecules | August 2020 | October 2023 | Allow | 38 | 2 | 1 | No | No |
| 16956779 | Oral Gene Carrier And Use Thereof | August 2020 | July 2022 | Allow | 24 | 1 | 1 | Yes | No |
| 16996635 | NOVEL METHODS OF TREATING NEUTORPENIA USING G-CSF PROTEIN COMPLEX | August 2020 | October 2022 | Allow | 26 | 2 | 1 | Yes | No |
| 16994404 | Use of Ultrarapid Acting Insulin | August 2020 | September 2022 | Allow | 25 | 2 | 1 | Yes | No |
| 16994464 | ANTIBODY FOR BINDING TO INTERLEUKIN 4 RECEPTOR | August 2020 | August 2023 | Allow | 36 | 1 | 1 | No | No |
| 16762942 | MULTI-DOMAIN ACTIVE PROTEIN FOR TREATING METABOLIC DISEASES | August 2020 | September 2023 | Allow | 41 | 2 | 1 | Yes | No |
| 16984990 | INSULIN CONTAINING PHARMACEUTICAL COMPOSITIONS | August 2020 | April 2022 | Abandon | 20 | 0 | 1 | No | No |
| 16966694 | PHARMACEUTICAL COMPOSITION COMPRISING ACYLATED DERIVATIVE OF HUMAN INSULIN ANALOG AND PREPARATION METHOD THEREOF | July 2020 | April 2023 | Abandon | 33 | 2 | 0 | No | No |
| 16965797 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION AND CANCER | July 2020 | June 2024 | Allow | 46 | 1 | 1 | No | No |
| 16941290 | METHODS FOR TREATING HEART FAILURE USING GLUCAGON RECEPTOR ANTAGONISTIC ANTIBODIES | July 2020 | May 2022 | Allow | 22 | 1 | 0 | Yes | No |
| 16929342 | FIBROBLAST GROWTH FACTOR 1 (FGF1) MUTANT PROTEINS THAT SELECTIVELY ACTIVATE FGFR1B TO REDUCE BLOOD GLUCOSE | July 2020 | September 2022 | Allow | 26 | 1 | 1 | No | No |
| 16928441 | Methods For Treating Obesity And Nonalcoholic Fatty Liver Disease Or Nonalcoholic Steatohepatitis Using Glucagon Receptor Antagonistic Antibodies | July 2020 | February 2023 | Abandon | 31 | 1 | 1 | No | No |
| 16921422 | PHARMACEUTICAL COMPOSITION COMPRISING A GLP-1-AGONIST AND METHIONINE | July 2020 | August 2022 | Abandon | 26 | 1 | 0 | No | No |
| 16960254 | FGF21 VARIANT, FUSION PROTEIN AND APPLICATION THEREOF | July 2020 | April 2023 | Allow | 33 | 2 | 1 | Yes | No |
| 16959390 | METHOD OF INCREASING PROLIFERATION OF PANCREATIC BETA CELLS, TREATMENT METHOD, AND COMPOSITION | June 2020 | April 2023 | Allow | 33 | 2 | 1 | Yes | No |
| 16909755 | GATA3 INHIBITORS FOR THE PROMOTION OF SUBCUTANEOUS FAT DEPOSITION | June 2020 | December 2023 | Allow | 42 | 2 | 1 | Yes | No |
| 16955698 | TREATMENT OF EXERCISE-INDUCED HYPOGLYCEMIA IN TYPE 1 AND INSULIN USING TYPE 2 DIABETES | June 2020 | August 2023 | Abandon | 38 | 3 | 0 | No | No |
| 16893498 | FUSION PROTEINS AND METHODS OF USE | June 2020 | October 2021 | Allow | 16 | 1 | 0 | Yes | No |
| 16769774 | GLUCAGON-LIKE PEPTIDES | June 2020 | October 2022 | Allow | 28 | 2 | 1 | No | No |
| 16889783 | Engineered Erythroid Cells Including HLA-G Polypeptides and Methods of Use Thereof | June 2020 | September 2023 | Abandon | 39 | 1 | 1 | No | No |
| 16768600 | NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | May 2020 | November 2022 | Abandon | 30 | 1 | 1 | No | No |
| 16878097 | Therapies for Obesity, Diabetes and Related Indications | May 2020 | September 2022 | Abandon | 28 | 1 | 1 | No | No |
| 16870388 | METHOD FOR PRODUCING INSULIN-PRODUCING CELL FROM MESENCHYMAL STEM CELL, INSULIN-PRODUCING CELL, CELL STRUCTURE, AND PHARMACEUTICAL COMPOSITION | May 2020 | February 2024 | Allow | 45 | 2 | 1 | Yes | Yes |
| 16761606 | GLP-2 ANALOGS AND PEPTIBODIES FOR ADMINISTRATION BEFORE, DURING OR AFTER SURGERY | May 2020 | January 2023 | Allow | 32 | 1 | 1 | No | No |
| 16759536 | SHORT CHAIN CERAMIDE-BASED LIPIDS AND USES THEREOF | April 2020 | September 2022 | Allow | 29 | 1 | 1 | No | No |
| 16858383 | FUNCTIONALIZED MICROBUBBLE EMBODIMENTS FOR ULTRASOUND-MEDIATED TREATMENT AND METHODS OF MAKING AND USING THE SAME | April 2020 | July 2023 | Allow | 39 | 2 | 1 | Yes | No |
| 16855552 | GLUCAGON AND GLP-1 CO-AGONISTS FOR THE TREATMENT OF OBESITY | April 2020 | December 2021 | Abandon | 20 | 1 | 0 | No | No |
| 16851975 | METHOD OF PROMOTING BONE GROWTH BY AN ANTI-ACTRIIA ANTIBODY | April 2020 | August 2022 | Allow | 28 | 1 | 0 | No | No |
| 16755183 | GLUCOSE TRANSPORTER INHIBITOR-MODIFIED INSULIN FOR GLUCOSE-RESPONSIVE INSULIN DELIVERY | April 2020 | May 2023 | Allow | 37 | 2 | 0 | No | No |
| 16754772 | DIAGNOSIS OF CROHN'S DlSEASE AND ULCERATIVE COLITIS | April 2020 | September 2023 | Abandon | 41 | 1 | 1 | No | No |
| 16652407 | METHOD FOR TREATING COMPLICATIONS RELATED TO ACUTE OR CHRONIC HYPERGLYCEMIA | March 2020 | June 2023 | Allow | 38 | 2 | 1 | No | No |
| 16651765 | LONG-ACTING SINGLE-CHAIN INSULIN ANALOG AND CONJUGATE THEREOF | March 2020 | January 2022 | Abandon | 21 | 0 | 1 | No | No |
| 16828841 | METHODS FOR DELIVERING ETANERCEPT PREPARATIONS INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE | March 2020 | April 2022 | Allow | 24 | 2 | 1 | No | No |
| 16649903 | BIOMARKERS TO DETECT AND CHARACTERISE CANCER | March 2020 | March 2023 | Abandon | 36 | 0 | 1 | No | No |
| 16825955 | COMBINATION OF IL-4/IL-13 PATHWAY INHIBITORS AND PLASMA CELL ABLATION FOR TREATING ALLERGY | March 2020 | October 2023 | Allow | 43 | 1 | 1 | Yes | No |
| 16823493 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETIC COMPLICATIONS | March 2020 | January 2023 | Allow | 34 | 3 | 0 | Yes | No |
| 16818441 | Method of Detecting Cellular Reporting for Therapy Production | March 2020 | March 2024 | Allow | 48 | 4 | 1 | Yes | No |
| 16815250 | Methods For Treating Type 1 Diabetes Using Glucagon Receptor Antagonistic Antibodies | March 2020 | May 2022 | Allow | 26 | 1 | 1 | Yes | No |
| 16808010 | METHODS FOR TREATING ANEMIA IN A SUBJECT IN NEED THEREOF | March 2020 | January 2021 | Allow | 11 | 2 | 0 | Yes | No |
| 16795083 | METHODS FOR TREATING ANEMIA IN A SUBJECT IN NEED THEREOF | February 2020 | January 2021 | Allow | 11 | 2 | 0 | Yes | No |
| 16795015 | COMBINED USE OF GDF TRAPS AND ERYTHROPOIETIN RECEPTOR ACTIVATORS TO INCREASE RED BLOOD CELL LEVELS | February 2020 | August 2020 | Allow | 6 | 1 | 0 | Yes | No |
| 16795088 | METHODS FOR TREATING ANEMIA IN A SUBJECT IN NEED THEREOF | February 2020 | January 2021 | Allow | 11 | 2 | 0 | Yes | No |
| 16795021 | COMBINED USE OF GDF TRAPS AND ERYTHROPOIETIN RECEPTOR ACTIVATORS TO INCREASE RED BLOOD CELL LEVELS | February 2020 | September 2020 | Allow | 6 | 1 | 0 | Yes | No |
| 16795026 | COMBINED USE OF GDF TRAPS AND ERYTHROPOIETIN RECEPTOR ACTIVATORS TO INCREASE RED BLOOD CELL LEVELS | February 2020 | August 2020 | Allow | 6 | 1 | 0 | Yes | No |
| 16795076 | METHODS FOR STIMULATING PROLIFERATION OF ERYTHROID PROGENITOR CELLS | February 2020 | November 2020 | Allow | 9 | 1 | 0 | Yes | No |
| 16781304 | COMPOSITIONS AND METHODS FOR TREATING OBESITY AND HYPERPHAGIA | February 2020 | April 2022 | Allow | 26 | 1 | 1 | Yes | No |
| 16751538 | ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION | January 2020 | July 2022 | Allow | 30 | 1 | 1 | Yes | No |
| 16752386 | METHODS FOR TREATING DIABETES AND REDUCING BODY WEIGHT | January 2020 | December 2021 | Abandon | 22 | 0 | 1 | No | No |
| 16750432 | THERAPEUTIC METHODS FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS FOR PATIENTS WITH HIGH BASELINE HbA1c | January 2020 | February 2022 | Abandon | 25 | 1 | 0 | No | No |
| 16741658 | ISOLATED NUCLEIC ACIDS ENCODING ANTI-SORTILIN ANTIBODIES | January 2020 | July 2021 | Allow | 18 | 1 | 0 | No | No |
| 16630322 | INSULIN-TRANSFERRIN FUSION PROTEIN AND ITS PRODRUG, PROINSULIN-TRANSFERRIN, FOR OVERCOMING INSULIN RESISTANCE | January 2020 | May 2022 | Allow | 28 | 1 | 1 | Yes | No |
| 16731834 | THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE | December 2019 | January 2024 | Abandon | 48 | 2 | 1 | Yes | No |
| 16727848 | PHARMACEUTICAL COMBINATION FOR IMPROVING GLYCEMIC CONTROL AS ADD-ON THERAPY TO BASAL INSULIN | December 2019 | December 2021 | Abandon | 24 | 1 | 0 | No | No |
| 16723645 | GLUCAGON/GLP-1 AGONISTS FOR THE TREATMENT OF OBESITY | December 2019 | September 2021 | Allow | 21 | 1 | 0 | No | No |
| 16721357 | An inhalable dry powder pharmaceutical composition | December 2019 | December 2021 | Allow | 24 | 1 | 1 | Yes | No |
| 16714407 | ADMINISTRATION OF AN ANTI-ACTIVIN-A COMPOUND TO A SUBJECT | December 2019 | August 2022 | Allow | 32 | 2 | 0 | No | No |
| 16702870 | COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED DIABETES AND RELATED DISORDERS | December 2019 | April 2022 | Allow | 28 | 1 | 1 | No | No |
| 16697519 | ORAL COMPOSITION OF ANTI-TNF ALPHA ANTIBODIES | November 2019 | November 2021 | Abandon | 24 | 0 | 1 | No | No |
| 16684110 | GLUCAGON DERIVATIVES | November 2019 | July 2021 | Allow | 20 | 1 | 1 | No | No |
| 16609098 | TARGETING GAMMA-DELTA T CELLS IN OBESITY AND CACHEXIA | October 2019 | October 2022 | Abandon | 35 | 2 | 1 | No | No |
| 16663239 | INSULIN IMMUNOGLOBULIN FUSION PROTEINS | October 2019 | April 2022 | Allow | 29 | 2 | 1 | Yes | No |
| 16662776 | METHOD FOR INHIBITING CALCIFICATION OF A SMOOTH MUSCLE CELL (SMC) | October 2019 | November 2021 | Allow | 24 | 2 | 1 | No | No |
| 16607453 | PHARMACEUTICAL FORMULATION COMPRISING INCRETIN-INSULIN CONJUGATES | October 2019 | October 2022 | Allow | 36 | 3 | 1 | Yes | No |
| 16598713 | POLYPEPTIDE AND COMPOSITION THEREOF FOR TREATING DISEASES OF METABOLIC SYSTEM | October 2019 | October 2022 | Abandon | 36 | 2 | 1 | No | No |
| 16596446 | PEPTIDES FOR USE IN TREATMENT AND DIAGNOSIS OF TYPE 1 DIABETES | October 2019 | July 2021 | Abandon | 21 | 0 | 1 | No | No |
| 16500897 | Oligomer Extended Insulin-FC Conjugates | October 2019 | August 2022 | Allow | 34 | 2 | 1 | Yes | No |
| 16498634 | DETERMINATION METHOD AND KIT FOR DETERMINING POSSIBILITY OF REDUCED RENAL FUNCTION | September 2019 | July 2023 | Allow | 46 | 2 | 1 | No | No |
| 16497284 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A CHST15 INHIBITOR | September 2019 | March 2023 | Abandon | 42 | 0 | 1 | No | No |
| 16496386 | FUSION PROTEIN, PREPARATION METHOD THEREFOR AND USE THEREOF | September 2019 | May 2022 | Allow | 32 | 1 | 1 | No | No |
| 16495884 | INSULIN ANALOG COMPLEX WITH REDUCED AFFINITY FOR INSULIN RECEPTOR AND USE THEREOF | September 2019 | April 2023 | Allow | 43 | 4 | 1 | No | No |
| 16492824 | SINGLE-CHAIN INSULIN ANALOGUES STABILIZED BY A FOURTH DISULFIDE BRIDGE | September 2019 | July 2021 | Allow | 22 | 1 | 1 | Yes | No |
| 16566455 | PROTEIN AND PROTEIN CONJUGATE FOR DIABETES TREATMENT, AND APPLICATIONS THEREOF | September 2019 | August 2021 | Allow | 23 | 1 | 1 | No | No |
| 16563348 | CYTOTOXIC T CELL RESPONSE MODIFIERS | September 2019 | June 2023 | Allow | 46 | 1 | 1 | No | No |
| 16550973 | BIPHASIC SINGLE-CHAIN INSULIN ANALOGUES | August 2019 | June 2021 | Allow | 21 | 1 | 0 | No | No |
| 16546375 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION | August 2019 | October 2021 | Allow | 25 | 2 | 0 | No | No |
| 16546101 | BIOMARKERS OF FAST PROGRESSION OF CHRONIC KIDNEY DISEASE | August 2019 | January 2022 | Allow | 29 | 2 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHANDRA, GYAN.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 12.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner CHANDRA, GYAN works in Art Unit 1646 and has examined 869 patent applications in our dataset. With an allowance rate of 53.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 28 months.
Examiner CHANDRA, GYAN's allowance rate of 53.0% places them in the 16% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by CHANDRA, GYAN receive 1.61 office actions before reaching final disposition. This places the examiner in the 28% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by CHANDRA, GYAN is 28 months. This places the examiner in the 66% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +48.3% benefit to allowance rate for applications examined by CHANDRA, GYAN. This interview benefit is in the 91% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 27.7% of applications are subsequently allowed. This success rate is in the 52% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 56.7% of cases where such amendments are filed. This entry rate is in the 84% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 53% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 88.0% of appeals filed. This is in the 81% percentile among all examiners. Of these withdrawals, 77.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 102.9% are granted (fully or in part). This grant rate is in the 94% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 3.7% of allowed cases (in the 83% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.